Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy

Tytuł:
Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy
Autorzy:
Feng QZ
Chen XZ
Sun J
Lu MM
Wang Y
Wang Q
Zhang C
Temat:
trastuzumab combined with docetaxel
her-2+ breast cancer
tumor markers
analysis of therapeutic factors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
Cancer Management and Research, Vol Volume 13, Pp 8077-8084 (2021)
Wydawca:
Dove Medical Press, 2021.
Rok publikacji:
2021
Kolekcja:
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1179-1322
Relacje:
https://www.dovepress.com/analysis-of-the-effect-of-trastuzumab-combined-with-docetaxel-on-serum-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322
Dostęp URL:
https://doaj.org/article/e751eec727254c38810bbe3d390d161b  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.751eec727254c38810bbe3d390d161b
Czasopismo naukowe
Qi-Zhu Feng,1– 3 Xian-Zhi Chen,2 Jie Sun,4 Man-Man Lu,5 Yong Wang,6 Qi Wang,4 Chao Zhang1,3 1Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230032, Anhui, People’s Republic of China; 2Department of Breast Surgery, First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People’s Hospital), Huainan, 232007, Anhui, People’s Republic of China; 3School of Continuing Education, Anhui Medical University, Hefei, 230032, Anhui, People’s Republic of China; 4Department of General Surgery, First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People’s Hospital), Huainan, 232007, Anhui, People’s Republic of China; 5Department of Laboratory Medicine, First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People’s Hospital), Huainan, 232007, Anhui, People’s Republic of China; 6Department of Medical Oncology, First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People’s Hospital), Huainan, 232007, Anhui, People’s Republic of ChinaCorrespondence: Chao ZhangDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230032, Anhui, People’s Republic of ChinaTel +86-13956053990Email zhangchaolove88@163.comObjective: To explore the influence of trastuzumab (TZ) combined with docetaxel (DTX) on serum tumor markers (TMs) in the treatment of human epidermal growth factor receptor 2-positive (HER-2+) breast cancer (BC) and to analyze the factors influencing therapeutic efficacy.Methods: Ninety-six patients with HER-2+ BC treated in the First Affiliated Hospital of Anhui University Of Science and Technology from January 2019 to December 2020 were selected. According to different treatment plans, the patients were divided into two arms with 48 cases each. The control group (CG) was treated with DTX, and the research group (RG) was given TZ combined with DTX (TZ+DTX). The two arms were compared regarding the following aspects: curative effects, adverse reaction, alterations of TMs and inflammatory factors (IFs), and quality of life. Logistic regression analysis was performed to analyze the factors affecting the efficacy of patients.Results: After treatment, the TMs carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125 and CA15-3 were significantly lower in RG compared with CG. The levels of IFs C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were also lower in CG. The overall response rate and the Karnofsky performance status (KPS) score were significantly higher in RG. No evident difference was observed in the total incidence of adverse reactions between the two arms. The high expression of CEA, CA125 and CA15-3 as well as DTX monotherapy increased the risk of adverse prognosis.Conclusion: TZ+DTX can effectively improve the clinical efficacy of HER-2+ BC patients and reduce their levels of serum TMs and IFs.Keywords: trastuzumab combined with docetaxel, HER-2+ breast cancer, tumor markers, analysis of therapeutic factors

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies